Tifsi
Generic Name
Tifozin 1 mg tablet
Manufacturer
MediCo Pharma Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| tifsi 1 mg tablet | ৳ 2.00 | ৳ 20.00 |
Description
Overview of the medicine
Tifsi 1 mg Tablet is an oral antidiabetic medication belonging to the Sodium-Glucose Co-transporter 2 (SGLT2) inhibitor class. It is used to improve glycemic control in adults with type 2 diabetes mellitus. It works by increasing the excretion of glucose in the urine, thereby lowering blood sugar levels.
Uses & Indications
Dosage
Adults
The recommended starting dose is Tifsi 1 mg once daily in the morning, with or without food. The dose may be increased based on efficacy and tolerability, up to a maximum of 2 mg once daily.
Elderly
No dosage adjustment is recommended based on age alone. However, renal function should be assessed before initiating and periodically during treatment.
Renal_impairment
Not recommended for initiation in patients with eGFR < 30 mL/min/1.73 m². In patients with eGFR ≥ 30 mL/min/1.73 m² already on Tifsi, dose adjustment may not be required, but close monitoring is advised. Discontinue if eGFR consistently falls below 30 mL/min/1.73 m².
How to Take
Take Tifsi 1 mg tablet orally once daily in the morning, with or without food. Swallow the tablet whole with water. Do not crush, cut, or chew the tablet.
Mechanism of Action
Tifozin selectively inhibits SGLT2, a protein primarily responsible for reabsorbing glucose in the renal proximal tubules. By inhibiting SGLT2, Tifozin reduces glucose reabsorption and increases urinary glucose excretion, leading to a reduction in plasma glucose concentrations. This mechanism is independent of insulin secretion and insulin sensitivity.
Pharmacokinetics
Onset
Within hours of administration, significant glucosuria observed.
Excretion
Excreted primarily via urine (approximately 70-80% as metabolites) and feces (approximately 20% as metabolites).
Half life
Approximately 10-14 hours, allowing for once-daily dosing.
Absorption
Rapidly absorbed after oral administration. Peak plasma concentrations are reached within 1-2 hours.
Metabolism
Primarily metabolized via UGT1A9-mediated O-glucuronidation. Minor metabolism via CYP enzymes.
Side Effects
Contraindications
- Hypersensitivity to the active substance or to any of the excipients.
- Severe renal impairment (eGFR < 30 mL/min/1.73 m²), end-stage renal disease, or patients on dialysis.
Drug Interactions
Lithium
SGLT2 inhibitors may decrease serum lithium concentrations. Monitor serum lithium levels more frequently.
Diuretics
May increase the risk of dehydration and hypotension. Close monitoring of volume status and blood pressure is recommended.
Insulin and Insulin Secretagogues (e.g., Sulfonylureas)
May increase the risk of hypoglycemia. A lower dose of insulin or sulfonylurea may be required.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
In the event of an overdose, symptomatic and supportive treatment should be initiated. Tifozin is unlikely to be dialyzable. Monitor vital signs and blood glucose levels.
Pregnancy & Lactation
Not recommended during pregnancy, especially during the second and third trimesters, due to potential adverse effects on fetal renal development. It is unknown if Tifozin is excreted in human milk; therefore, Tifsi is not recommended during breastfeeding.
Side Effects
Contraindications
- Hypersensitivity to the active substance or to any of the excipients.
- Severe renal impairment (eGFR < 30 mL/min/1.73 m²), end-stage renal disease, or patients on dialysis.
Drug Interactions
Lithium
SGLT2 inhibitors may decrease serum lithium concentrations. Monitor serum lithium levels more frequently.
Diuretics
May increase the risk of dehydration and hypotension. Close monitoring of volume status and blood pressure is recommended.
Insulin and Insulin Secretagogues (e.g., Sulfonylureas)
May increase the risk of hypoglycemia. A lower dose of insulin or sulfonylurea may be required.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
In the event of an overdose, symptomatic and supportive treatment should be initiated. Tifozin is unlikely to be dialyzable. Monitor vital signs and blood glucose levels.
Pregnancy & Lactation
Not recommended during pregnancy, especially during the second and third trimesters, due to potential adverse effects on fetal renal development. It is unknown if Tifozin is excreted in human milk; therefore, Tifsi is not recommended during breastfeeding.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
36 months
Availability
Available in pharmacies and hospitals nationwide
Approval Status
Approved by regulatory authorities for use in Type 2 Diabetes Mellitus
Patent Status
Patented, expected expiry in 2038
Clinical Trials
Tifozin has been extensively studied in several Phase III clinical trials demonstrating its efficacy and safety in patients with type 2 diabetes. Post-marketing surveillance studies are ongoing.
Lab Monitoring
- Renal function (eGFR) should be assessed before initiation and periodically thereafter.
- Blood glucose and HbA1c levels to monitor glycemic control.
- Lipid profile (periodically, as SGLT2 inhibitors may slightly increase LDL-C).
- Electrolytes, especially in patients at risk of volume depletion.
Doctor Notes
- Educate patients about the importance of hydration and genital hygiene.
- Monitor renal function before and during treatment.
- Advise patients to seek immediate medical attention if symptoms of ketoacidosis (e.g., nausea, vomiting, abdominal pain) or Fournier's gangrene (e.g., tenderness, redness, swelling in the genital or perineal area) occur.
Patient Guidelines
- Maintain adequate hydration to prevent dehydration, especially during hot weather or exercise.
- Practice good personal hygiene to reduce the risk of genital and urinary tract infections.
- Report any symptoms of severe dehydration, ketoacidosis (e.g., nausea, vomiting, abdominal pain), or Fournier's gangrene immediately to your doctor.
- Carry a source of rapidly acting glucose (e.g., glucose tablets) in case of hypoglycemia, especially if taking insulin or sulfonylureas concurrently.
Missed Dose Advice
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and resume your regular dosing schedule. Do not take a double dose to make up for a missed one.
Driving Precautions
Tifsi generally does not affect the ability to drive or operate machinery. However, if used in combination with insulin or a sulfonylurea, there is an increased risk of hypoglycemia, which could impair driving ability. Patients should be advised to take precautions.
Lifestyle Advice
- Adhere to a balanced diet recommended by your healthcare provider or a registered dietitian.
- Engage in regular physical activity as advised by your doctor to help manage blood sugar.
- Monitor your blood sugar levels regularly as instructed.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Tifsi Brand
Other medicines available under the same brand name
